U.S. markets closed

GH Research PLC (GHRS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W
20.560.00 (0.00%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
Previous Close20.56
Open20.97
Bid16.00 x 21500
Ask21.40 x 1200
Day's Range20.56 - 21.21
52 Week Range15.08 - 26.91
Volume7,335
Avg. Volume101,596
Market Cap1.039B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GH Research PLC
    Daily – Vickers Top Buyers & Sellers for 08/27/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    28 days agoArgus Research
View more
  • GlobeNewswire

    GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

    DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided business updates and reported financial results for the second quarter ended June 30, 2021. Business Updates Corporate Updates In June 2021, we completed our initial public offering, in which we issued and sold an aggregate of 11,499,999 ordinary shares, including those issu

  • Benzinga

    Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies

    Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential of 5-MeO-DMT for the treatment of psychiatric and neurological disorders, is now listing its stock on the Nasdaq under the symbol “GHRS.” The company had an IPO of 10 million shares at an initial price of $16 per share for total proceeds of approximately $160 million. Shares opened for the public last Friday at $22. The company’s flagship drug candidate, GH001 (an inhalable 5-MeO-DMT a